The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Digital measurement of functional status of patients with glioblastoma.
 
Yasaman Damestani
Employment - Biogen; Karyopharm Therapeutics
Stock and Other Ownership Interests - Biogen; Karyopharm Therapeutics
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - Karyopharm Therapeutics; Mevion Medical Systems; Sapience Therapeutics; Tocagen; ZappRx
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - ViewRay; Xcision Medical Systems
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
Kevin A. Camphausen
Employment - Fairfax Radiological Consultants (I)
 
Michael Weller
Honoraria - Adastra Pharmaceuticals; Merck Serono; MSD; Nerviano Medical Sciences; Philogen
Consulting or Advisory Role - Bristol-Myers Squibb; Karyopharm Therapeutics; Medac; Orbus Therapeutics; Tocagen; Ymabs Therapeutics Inc
Research Funding - Apogenix (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Quercegen Pharmaceuticals (Inst)
 
Evanthia Galanis
Consulting or Advisory Role - Agios (Inst); Gradalis; Karyopharm Therapeutics (Inst); MedImmune (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); TRACON Pharma (Inst)
 
Martin J. Van Den Bent
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; Agios; Bayer; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol-Myers Squibb; carthera; Celgene; Eoche; Genenta Science; Nerviano Medical Sciences
Research Funding - Abbvie (Inst)
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; WuXi Biologics; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; Bioasis Technologies; Cure Brain Cancer Foundation; Debiopharm Group; DelMar Pharmaceuticals; Genentech/Roche; GenomiCare; GlaxoSmithKline; InSightec; Janssen; Karyopharm Therapeutics; KIYATEC; Magnolia Innovation; Merck; Mundipharma Research; Novartis; Prelude Therapeutics; resTORbio; Samus Therapeutics; Sapience Therapeutics; Tocagen; Voyager Therapeutics
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - VBI Vaccines
 
Andrew B. Lassman
Honoraria - Abbott Molecular
Consulting or Advisory Role - Bayer; BioClinica; Elsevier; FORMA Therapeutics; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; QED Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); RTOG Foundation (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Abbott Molecular; AbbVie; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Novartis; Orbus Therapeutics; Pfizer; QED Therapeutics
 
Andreas Felix Hottinger
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Novocure
Speakers' Bureau - Novocure
Research Funding - Novocure
 
Louis B. Nabors
Consulting or Advisory Role - BTG; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Development of novel inhibitors to HuR through NCI funded peer reviewed research.
Other Relationship - University of Pennsylvania; ZIOPHARM Oncology
 
J Paul Duic
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Kai Li
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Yang Liu
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Shijie Tang
Employment - Karyopharm Therapeutics
Honoraria - Karyopharm Therapeutics
 
Sharon Tamir
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Eran Shacham
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - holding patents (8999996, 9079865, 9714226, PCT/US12/048319, and I574957) on hydrazide-containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 2012000928) on hydrazide-containing nuclear tr
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)